Zogenix Announces FDA Agreement to Proceed with Resubmission of FINTEPLA® NDA
The Type A meeting was conducted to review the two issues identified in the Refusal to File (RTF) letter issued by the
“We are very pleased with the outcome of our meeting with the
Forward Looking Statement
Senior Director, Corporate Communications
+1 (510) 788 8732 | email@example.com
+1 (646) 597-6987 | Andrew@lifesciadvisors.com
Source: Zogenix, Inc.